CG Oncology (NASDAQ:CGON) Director James Mulay Sells 15,600 Shares

CG Oncology, Inc. (NASDAQ:CGON) Director James Mulay sold 15,600 shares of the business’s stock in a transaction dated Friday, April 17th. The shares were sold at an average price of $73.01, for a total value of $1,138,956.00. Following the completion of the transaction, the director directly owned 15,600 shares in the company, valued at $1,138,956. This represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

James Mulay also recently made the following trade(s):

• On Monday, March 16th, James Mulay sold 1,964 shares of CG Oncology stock. The shares were sold at an average price of $63.50, for a total value of $124,714.00.

CG Oncology Trading Down 4.1%

NASDAQ CGON traded down $3.03 during trading hours on Monday, hitting $70.40. 930,493 shares of the company’s stock were exchanged, compared to its average volume of 1,323,766. The firm has a market cap of $5.94 billion, a price-to-earnings ratio of -34.01 and a beta of 0.70. The stock has a 50-day simple moving average of $62.33 and a 200 day simple moving average of $50.60. CG Oncology, Inc. has a 1-year low of $19.91 and a 1-year high of $73.56.

CG Oncology (NASDAQ:CGON) last issued its quarterly earnings results on Friday, February 27th. The company reported ($0.51) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.61) by $0.10. The business had revenue of $2.32 million during the quarter. On average, sell-side analysts anticipate that CG Oncology, Inc. will post -2.57 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on CGON shares. Wall Street Zen upgraded shares of CG Oncology from a “sell” rating to a “hold” rating in a research report on Saturday, April 11th. Truist Financial lifted their price target on shares of CG Oncology from $66.00 to $75.00 and gave the company a “buy” rating in a research note on Tuesday, February 10th. The Goldman Sachs Group reiterated a “buy” rating and set a $82.00 price objective on shares of CG Oncology in a report on Monday, January 12th. Morgan Stanley set a $93.00 price objective on shares of CG Oncology in a research report on Friday, January 9th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of CG Oncology in a research note on Wednesday, January 21st. Eleven analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, CG Oncology presently has an average rating of “Moderate Buy” and a consensus target price of $79.00.

Hedge Funds Weigh In On CG Oncology

A number of large investors have recently modified their holdings of the company. Vanguard Group Inc. grew its position in CG Oncology by 11.4% in the 3rd quarter. Vanguard Group Inc. now owns 6,577,281 shares of the company’s stock valued at $264,933,000 after purchasing an additional 670,770 shares during the period. Wellington Management Group LLP increased its stake in CG Oncology by 8.8% during the 4th quarter. Wellington Management Group LLP now owns 5,999,790 shares of the company’s stock valued at $249,111,000 after purchasing an additional 487,011 shares in the last quarter. Price T Rowe Associates Inc. MD raised its holdings in CG Oncology by 116.7% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 3,443,144 shares of the company’s stock worth $142,961,000 after buying an additional 1,854,386 shares during the last quarter. State Street Corp raised its holdings in CG Oncology by 46.4% during the fourth quarter. State Street Corp now owns 2,996,695 shares of the company’s stock worth $124,423,000 after buying an additional 950,028 shares during the last quarter. Finally, Alliancebernstein L.P. lifted its stake in shares of CG Oncology by 15.0% in the second quarter. Alliancebernstein L.P. now owns 2,164,214 shares of the company’s stock valued at $56,270,000 after buying an additional 281,637 shares in the last quarter. 26.56% of the stock is currently owned by institutional investors.

CG Oncology Company Profile

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.